Erowid References Database
Amstrong BD, Paik E, Chhith S, Lelievre V, Waschek JA, Howard SG.
“POTENTIATION OF @L)-3,4=METHYLENEDIOXYMETHAMPHETAMINE (MDMA)-INDUCED TOXICITY BY THE SEROTONIN 2A RECEPTOR PARTIAL AGONIST D-LYSERGIC ACID DIETHYLAMIDE (LSD), AND THE PROTECTION OF SAME BY THE SEROTONIN 2A/2C RECEPTOR ANTAGONIST MDL 11,939”.
Neuroscience Research Communications. 2004;35(2).
To elucidate the role of the serotonin ( ~-HT)~A/x receptors in 3,4-
methylenedioxymethamphetamine (MDMA)-induced neurotoxicity, MDMA was administered to rats and the presence of the serotonin transporter (5HTT) was assessed at the protein level with immunohistochemistry (IHC), and the RNA level with a Northern blotting technique. d-lysergic acid diethylamide (LSD) and MDL 11,939 were given in conjunction with MDMA in order to assess the importance of 5-HT receptors in MDMA-induced neurotoxicity. The hypothesis is that the MDMA + LSD-treated animals should have more neurotoxicity as measured by loss of 5-HTTs compared to the MDMA-treated animals. Moreover, the loss of 5-HTTs should be attenuated in animals given the combination of MDMA + MDL 11,939, as the latter drug is a selective ~-HT~A/~c antagonist. The results showed that MDMA-induced neurotoxicity was dose dependently increased by LSD. Moreover, the drug MDL 11,939 attenuated MDMA-induced neurotoxicity, suggesting that 5-HT2A/2C receptors are involved in MDMA-induced neurotoxicity.
[ Cite HTML